At ASCRS 2018 in Washington, DC, a group of surgeons experienced in interventional glaucoma therapies sat down to discuss the roles of selective laser trabeculoplasty (SLT) and microinvasive glaucoma surgery (MIGS) for treatment of open angle glaucoma (OAG).
Laser Trabeculoplasty has a long track record of effectively lowering the IOP while presenting relatively low risk to those receiving this treatment. Selective Laser Trabeculoplasty has two key advantages over Argon Laser Trabeculoplasty: (1) it is repeatable;
The response to Laser Trabeculoplasty appears to be dependent upon the pre-treatment intraocular pressure (IOP). In other words, the higher the IOP before treatment, the better the response to Laser Trabeculoplasty.
Selective Laser Trabeculoplasty (SLT) may be repeated multiple times so long as there is an initial IOP-lowering response to the first treatment.[4]
